is being presented by Kay Bross, Program Director, Member and Vendor Relations, with SAFE-BioPharma Association and airs on Wednesday, July 28th, 2010. For more details or to register for this event, please visit our site at www.fxconferences.com
Many large pharmaceutical companies are transitioning to the SAFE-BioPharma digital identity and digital signature standard. The standard was developed by a consortium of biopharmaceutical and related companies with participation from the US FDA and the European Medicines Agency, and is used to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.
These sponsors are now asking CROs to obtain the necessary SAFE-BioPharma credentials to complete a fully electronic communication/transaction sharing circle. The payoff is faster exchanges and more readily accessible records, with accelerated turnaround for trial contract execution. Also, R&D eLab Notebook entries are secured into the future, and can be used as court evidence.
But how exactly do these digital identities and signatures differ from other electronic signatures, and what are the legal implications of using one over the other? In this audio conference, attendees get all the answers from Kay Bross of SAFE-BioPharma Association, the non-profit group that created and manages the SAFE-BioPharma® digital identity and digital signature standard.
